Cozadd Bruce C's Form 4 filing
Jazz Pharmaceuticals plc (JAZZ) · filed Oct 5, 2022
- Accession no.
- 0001765581-22-000116
- Filed
- Oct 5, 2022
- Trade date
- Oct 3, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $6.10M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cozadd Bruce CCIK 0001193210 | Director, Officer (Chairman & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 3, 2022 | Ordinary Shares | MOption exerciseAcquired | +62,905 | $59.13 | +$3,719,572.65 | 419,213 | Direct | |
| Oct 3, 2022 | Ordinary Shares | SSaleDisposed | −13,791 | $134.02F2 | −$1,848,269.82 | 405,422 | Direct | |
| Oct 3, 2022 | Ordinary Shares | SSaleDisposed | −23,646 | $135.18F3 | −$3,196,466.28 | 381,776 | Direct | |
| Oct 3, 2022 | Ordinary Shares | SSaleDisposed | −7,748 | $135.80F4 | −$1,052,178.4 | 374,028 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 3, 2022 | Ordinary Shares | MOption exerciseDisposed | −62,905 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $133.56 to $134.54. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.
- F3
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $134.57 to $135.56. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.
- F4
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $135.57 to $136.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.